Nasdaq:GDRX
GoodRx Holdings, Inc.
GoodRx is a leading digital health marketplace that connects consumers with pharmacies to offer transparent prescription drug pricing and access.
Key Metrics
Investment Thesis
Bull Case
GoodRx presents a compelling growth story as it successfully monetizes its data assets through diverse revenue streams beyond simple advertising. The transition to consistent profitability and strong positive operating cash flow suggests the business model has achieved sustainable unit economics at scale. With the rising trend of out-of-pocket drug costs, GoodRx's value proposition is increasingly critical for consumers seeking affordable medication access.
Bear Case
Valuation multiples may be stretched given that revenue growth has been relatively flat over the last five years, hovering between $750M and $800M. The company carries significant long-term debt obligations totaling $483.3M, which could constrain financial flexibility during periods of rising interest rates or economic downturns. Furthermore, the substantial retained earnings deficit indicates historical burn that, while reversed recently, still reflects a long path to building deep liquidity buffers.
About GoodRx Holdings, Inc.
GoodRx Holdings operates as a digital health platform connecting consumers with pharmacies to provide transparent prescription drug pricing and access. Serving millions of customers across the United States, the company generates revenue primarily through member subscriptions and partnerships with healthcare providers and payers. Its ecosystem leverages big data analytics to negotiate lower prices and improve patient adherence to medication regimens.
Analysis
Management Discussion
The company demonstrated a strong turnaround in recent fiscal performance, transitioning from net losses in 2023 to solid profitability with net income reaching $30.4M in the latest year. This improvement was supported by robust operating cash flow of $167.9M and a significant reduction in working capital needs, evidenced by a substantial increase in accounts receivable alongside manageable changes in payables. However, investors should note that while revenue grew to nearly $800M, the company still allocated over $430M in goodwill, indicating continued investment in acquisitions or past M&A activity that requires careful monitoring for integration success.
Industry Overview
The prescription drug pricing transparency sector is experiencing rapid evolution as federal and state regulations increasingly demand clearer pricing information for consumers. This regulatory shift has disrupted traditional pharmacy benefit models, creating opportunities for data-driven platforms that can facilitate direct negotiations between patients and pharmacies. The industry is characterized by high customer acquisition costs but potentially high lifetime value through subscription-based membership models.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $766.6M | $750.3M | $792.3M | $796.9M |
| Cost of Revenue | $65.1M | $66.9M | $48.2M | $57.6M |
| Gross Profit | $701.5M | $683.3M | $744.1M | $739.3M |
| Operating Expenses | $699.7M | $710.3M | $678.3M | $651.8M |
| Operating Income | $1.7M | $-27.0M | $65.8M | $87.5M |
| R&D | $143.1M | $135.8M | $123.7M | $121.0M |
| G&A | $144.8M | $125.5M | $117.9M | $114.0M |
| Marketing | $357.6M | $341.3M | $367.1M | $331.6M |
| Stock-Based Comp | $120.2M | $104.8M | $99.0M | $76.6M |
| D&A | $54.2M | $107.7M | $69.5M | $85.2M |
| Depreciation | $4.6M | $4.8M | $4.5M | $4.2M |
| Amortization | $23.2M | $59.0M | $8.8M | $11.9M |
| Other OpEx | $54.2M | $107.7M | $69.5M | $85.2M |
| Non-Operating Income | $-25.0M | $-28.6M | $-34.4M | $-31.0M |
| Interest Income | $9.3M | $32.2M | $23.3M | $10.9M |
| Pre-Tax Income | $-23.2M | $-55.6M | $31.5M | $56.5M |
| Income Tax | $9.6M | $-46.7M | $15.1M | $26.1M |
| Continuing Ops | $-32.8M | $-8.9M | $16.4M | $30.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-32.8M | $-8.9M | $16.4M | $30.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-32.8M | $-8.9M | $16.4M | $30.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $919.7M | $872.8M | $659.3M | $643.1M |
| Cash & Equivalents | $757.2M | $672.3M | $448.3M | $261.8M |
| Accounts Receivable | $117.1M | $143.6M | $145.9M | $235.7M |
| Prepaid Expenses | $45.4M | $56.9M | $65.0M | $47.2M |
| Other Current Assets | $0 | $0 | $0 | $98.3M |
| Long-Term Assets | $684.9M | $716.0M | $728.8M | $761.0M |
| PP&E (Net) | $19.8M | $15.9M | $12.7M | $12.3M |
| Goodwill | $412.1M | $410.8M | $410.8M | $430.3M |
| Operating Leases | $35.9M | $29.9M | $27.8M | $28.8M |
| Other LT Assets | $198.1M | $244.4M | $262.6M | $274.5M |
| Total Assets | $1.60B | $1.59B | $1.39B | $1.40B |
| Current Liabilities | $76.3M | $122.6M | $123.9M | $246.0M |
| Accounts Payable | $17.7M | $36.3M | $14.1M | $19.4M |
| Current Debt | $7.0M | $8.8M | $5.0M | $5.0M |
| Current Leases | $4.1M | $6.2M | $5.6M | $4.8M |
| Deferred Revenue | $7.9M | $7.1M | $6.0M | $6.7M |
| Taxes Payable | — | — | $1.5M | $0 |
| Other Current Liab | $39.6M | $64.2M | $91.6M | $210.1M |
| Long-Term Liabilities | $713.5M | $704.3M | $539.5M | $541.8M |
| Long-Term Debt | $651.8M | $647.7M | $486.7M | $483.3M |
| LT Operating Leases | $54.1M | $48.4M | $46.0M | $49.8M |
| Other LT Liab | $7.6M | $8.2M | $6.8M | $8.7M |
| Total Liabilities | $789.8M | $826.8M | $663.4M | $787.8M |
| Shareholders' Equity | $814.8M | $762.0M | $724.7M | $616.3M |
| Retained Earnings | $-1.45B | $-1.46B | $-1.44B | $-1.41B |
| Total L&E | $1.60B | $1.59B | $1.39B | $1.40B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-32.8M | $-8.9M | $16.4M | $30.4M |
| Non-Cash Adjustments | $171.4M | $48.9M | $168.5M | $33.8M |
| Working Capital Changes | $8.3M | $98.3M | $-955.0K | $103.7M |
| Cash from Operations | $146.8M | $138.3M | $183.9M | $167.9M |
| Capital Expenditures | $4.0M | $1.0M | $1.2M | $3.5M |
| Cash from Investing | $-210.5M | $-55.8M | $-70.3M | $-120.0M |
| Debt Issuances | $0 | — | $472.0M | $0 |
| Debt Repayments | $7.0M | $5.3M | $639.0M | $5.0M |
| Share Buybacks | $101.7M | $104.0M | $158.8M | $216.4M |
| Cash from Financing | $-120.2M | $-167.4M | $-337.5M | $-234.5M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-183.9M | $-84.9M | $-223.9M | $-186.5M |
| Beginning Cash | $941.1M | $757.2M | $672.3M | $448.3M |
| Ending Cash | $757.2M | $672.3M | $448.3M | $261.8M |
Frequently Asked Questions
How does GoodRx Holdings, Inc. make money?
The company's revenue is driven by its consumer-facing price transparency platform, pharmacy network partnerships, and payer solutions that utilize its data analytics for formulary management and benefit design. Additionally, the business leverages its proprietary data assets to create new revenue streams through strategic collaborations with pharmaceutical manufacturers and health systems.
What are the main risks for GDRX?
Regulatory headwinds regarding price transparency mandates could erode margins if the company is forced to share sensitive pricing data with competitors or insurers without compensation. Intense competition from large pharmacy benefit managers and other digital health startups poses a threat to its market share and ability to maintain high membership growth rates. Dependence on third-party pharmacy partners introduces operational risks, as any disruption in network availability or adherence to GoodRx's quality standards could impact customer trust. Fluctuations in drug prices or reimbursement rates from payers could significantly alter the revenue mix and profitability of its various business segments.
What is GDRX's competitive advantage?
GoodRx maintains a robust competitive moat through its vast proprietary dataset on prescription drug pricing, which enables real-time price comparison and negotiation capabilities. The company benefits from high network effects as it expands its pharmacy partner base, thereby increasing the range of accessible medications for its growing user community. Its direct-to-consumer brand recognition and seamless digital experience create significant switching costs for users compared to traditional search methods.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.